Drugs in Dev. Infections and Infectious Diseases
Undisclosed
Ireland 
Lead Product(s) : Sulopenem
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Expanded Access Use of Sulopenem Etzadroxil/Probenecid for Complicated Urinary Tract Infection
Details : Undisclosed
Product Name : Undisclosed
Product Type : Antibiotic
Upfront Cash : Inapplicable
December 24, 2020
Lead Product(s) : Sulopenem
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Icosapent Ethyl
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The trial objective is the effect of VASCEPA vs usual care on high-sensitivity C-reactive protein levels from baseline to 14 days in adults with a COVID-19-positive diagnosis.
Product Name : Vascepa
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 21, 2020
Lead Product(s) : Icosapent Ethyl
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Nitric Oxide
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Study to investigate antiviral activity and improvement in oxygenation and pulmonary arterial pressure in patients suffering from COVID-19 got clearance from Health Canada.
Product Name : INOmax
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 04, 2020
Lead Product(s) : Nitric Oxide
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
